Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma

Follicular Lymphoma Clinical Trial

— GAUDEALIS  

Official title:

Idelalisib Plus Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma: a Phase 2, Single-arm, Multicentric Study

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03890289
• Other study ID #: FIL_GAUDEALIS
• Status: Terminated
• Phase: Phase 2
• Start date: October 18, 2019
• Est. completion date: May 10, 2023

Study information

• Verified date: July 2023
• Source: Fondazione Italiana Linfomi - ETS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single arm, prospective, multi-centric, phase II study. Patients with histologically confirmed follicular lymphoma, in need of a systemic approach and failing (i.e. with refractory disease [no response or response lasting less than 6 months at any previous line of treatment] or with a proven disease relapse) at least 2 previous lines of treatment, including any antibody directed against the CD20 antigen-containing chemotherapy, will undergo a combined chemo-free treatment with obinutuzumab and idelalisib.

Description:

Single arm, prospective, multi-centric, phase II study. Patients with histologically confirmed follicular lymphoma, in need of a systemic approach and failing (i.e. with refractory disease [no response or response lasting less than 6 months at any previous line of treatment] or with a proven disease relapse) at least 2 previous lines of treatment, including any antibody directed against the CD20 antigen-containing chemotherapy, will undergo a combined chemo-free treatment with obinutuzumab and idelalisib. Obinutuzumab will be administered intravenously at a flat dose of 1000 mg on day 1, 8, 15 of the first cycle, then repeated on day 1 of each subsequent cycle, for 6 cycles (each cycle is completed in 28 days). Idelalisib will be given concomitantly with obinutuzumab and on a daily 150 mg bid schedule. For patients achieving at least a partial response at the end of induction, a maintenance phase with obinutuzumab is scheduled (on day 1 every two months for two years or until progression or unacceptable toxicity, whichever comes first) If one of the two drugs has to be permanently discontinued due to any cause, patient may continue treatment with the other agent if it is judged to be a clinical benefit. Patients with at least a stable disease will enter the follow-up phase and will be followed with repeated CT scans every six months for two years or until death/progression occurs (whichever comes firsts). Patients with progressive disease, whenever progression is documented, will enter a survival follow up period of two years after PD was documented. These patients are however considered evaluable for OS.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: May 10, 2023
• Est. primary completion date: April 29, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion criteria Relapsed or refractory, histologically confirmed CD20-positive follicular non-Hodgkin's lymphoma, grade 1, 2 or 3a according to WHO 2017 classification.

• Age 18 = years
• At least 2 prior systemic therapies for follicular lymphoma including both any antibody directed against the CD20 antigen and a chemotherapy combination.
• Treatment indications, with the presence of at least one of the following:
• bulky disease (nodal or extranodal mass - except spleen -more than 7 cm in its greater diameter or involvement of at least 3 nodal or extranodal sites, each with a diameter equal to or greater than 3 cm);
• at least one B-symptom (fever > 38°C of unclear etiology, night sweats, weight loss greater than 10% of body weight in the prior 6 months);
• symptomatic splenomegaly;
• compression syndrome (i.e. of orbits, ureters, gastrointestinal tract, biliary tract);
• lymphoma-related cytopenias (hemoglobin < 10 g/dL and/or platelets < 100.000/mmc and/or neutrophils < 1.500/mmc);
• pleural or peritoneal serous effusions;
• lactate dehydrogenase elevation.
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 2.
• Adequate hematological function, unless abnormalities due to underlying disease, within 28 days prior to signing informed consent, defined as follows: neutrophils > 1.500/mmc, platelets > 75.000/mmc, hemoglobin > 8,0 g/dL with transfusion independence.
• Capacity and willingness to adhere to study visit schedule and specific protocol procedures.
• Willingness to sign a written informed consent.
• Compliance with effective contraception without interruption, from 28 days before treatment start up (i.e., during the screening phase) to 18 months after treatment discontinuation, agreeing not to donate the semen during treatment and for 18 months after discontinuation (if the patient is male), or to undergo ongoing pregnancy test during the course of the study (if the patient is female).
• Patients must agree to undergo JPJ prophylaxis throughout the treatment period and 2-6 months thereafter (before consulting with Medical Monitor). Exclusion criteria Grade 3b follicular non-Hodgkin's lymphoma or evidence of transformation to high-grade non-Hodgkin's lymphoma.
• Central nervous system or leptomeningeal involvement by lymphoma.
• Major surgery (excluding any lymph node biopsy) within 28 days prior to signing informed consent.
• Seropositivity for HBV or evidence of active infection (HBsAg positivity, or HBsAg negativity with positive anti-HBs/anti-HBc and detectable viral DNA load); if viral load is negative or undetectable, the patient is eligible, provided their HBsAg negativity.
• Positive viral HCV RNA
• Seropositivity for HIV, regardless of viral load.
• Known history of drug induced liver injury, chronic active hepatitis C (HCV), chronic active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis, primary biliary cirrhosis, on-going extra-hepatic obstruction caused by cholelithiasis, cirrhosis of the liver or portal hypertension
• Known history of drug induced pneumonitis
• On-going inflammatory bowel disease
• On-going alcohol or drug addiction
• Life expectancy lower than 6 months.
• Prior history of malignancies, other than follicular lymphoma, unless the patient has been free for at least 10 years (exceptions: localized non-melanoma skin cancer ad carcinoma in situ of the cervix).
• Any of the following laboratory abnormalities: liver enzymes (AST/SGOT and/or ALT/SGPT) > 2.5-fold the upper limit of normal (except of liver involvement by lymphoma); total bilirubin > 1.5 mg/dL (except for patients with known Gilbert's disease or biliary tree compression by lymphoma masses); creatinine clearance < 30 mL/min.
• Uncontrolled intercurrent illness.
• Known hypersensitivity or allergy to murine products or to any of the medicaments under investigation.
• Pregnancy or breastfeeding, or unwillingness to comply with adequate contraception.
• Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the patient from signing the informed consent or which may place the patient at unacceptable risk if participating in the study.
• Any evidence of ongoing bacterial, viral and fungal infection.

Related Conditions & MeSH terms

• Follicular Lymphoma
• Lymphoma
• Lymphoma, Follicular

Intervention

Drug:
• Idelalisib
Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma
• Obinutuzumab
Idelalisib Plus Obinutuzumab In Patients With Relapsed/Refractory Follicular Lymphoma

Locations

Country	Name	City	State
Italy	Policlinico S.Orsola-Malpighi - Istituto di Ematologia "Seragnoli"	Bologna
Italy	Azienda Ospedaliera Universitaria Careggi - Unità funzionale di Ematologia	Firenze
Italy	AOU Maggiore della Carità di Novara - SCDU Ematologia	Novara
Italy	Azienda sanitaria-universitaria integrata Trieste (ASUITS) - SC Ematologia	Trieste

Sponsors (1)

Lead Sponsor	Collaborator
Fondazione Italiana Linfomi - ETS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary Endpoint - Overall response rate (ORR)	Investigator's assessed Overall response rate at the end of induction phase of patients treated with a chemo-free combination with obinutuzumab and idelalisib. Overall response rate is defined as the proportion of patients with at least a partial response	through the completion of the study
Secondary	Secondary Endpoints 1 - Overall survival (OS) rate	Overall survival rate	at the end of induction phase of patients treated with a chemo-free. Through the completion of the study
Secondary	Secondary Endpoints 2 - Progression-free survival (PFS) rate	Progression-free survival rate	at the end of induction phase of patients treated with a chemo-free. Through the completion of the study
Secondary	Secondary Endpoints 3 - patients' withdrawal rate	patients' withdrawal rate, incidence and nature of any severe adverse events hospitalization rate throughout the study, and patients' compliance to oral treatment, incidence of any adverse events occurring during and right after treatment	at the end of induction phase of patients treated with a chemo-free. Through the completion of the study